We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

WE.FOR.YOU

“We want to make your life easier with high-quality products coupled with efficient and reliable services.”

Birgit Jansen

Head Contract Manufacturing Business

About us

As a true global partner, we know how to bring products to market at competitive cost, with current deliveries spanning well over 100 countries worldwide.

Grünenthal PRO offers a unique combination of highly efficient production, with very high standards of quality and service level. We are able to adapt and segment our operation to different business models, from high volume generics, to high complexity portfolio driven business models, as well as continuous improvement frameworks for the highly competitive biopharma market.

As a family owned company, it is our long term commitment that drives sustainable partnerships with our customers.

Serialisation

All packaging sites are equipped with serialization and aggregation infrastructure to match the various national requirements.

Packaging

Impressions of the Grünenthal packaging center at our Headquarters in Aachen, Germany.

Full service in Latin America

Tour of our primary manufacturing site for supply of solid, semi-solid and liquid products throughout Latin America (amongst others approved by EMA, ANVISA, INVIMA).

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a € 2 billion company.

Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a € 2 billion company.
... Find out more